Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Dr. Kathy Gately

Clinical Senior Lecturer (Clinical Medicine)

 


Dr. Kathy Gately graduated with a BSc from University College Dublin and a PhD from the Department of Biochemistry, National University of Ireland Galway in 2000. During her PhD she spent six months at the University of California Los Angeles. She then worked as a postdoctoral fellow in the Dept. of Haematology where she carried out research on the novel targeted agent Imatinib in CML patients. In 2004, Dr. Gately was appointed as a Clinical Lecturer with Prof. Ken O'Byrne in the Dept. of Clinical Medicine. She was instrumental in the establishment of the Lung Cancer Biobank which supports research and clinical trials within the Translational Oncology Research Group (TORG).The main focus of Dr. Gately's research group is (i) the identification of novel prognostic/predictive biomarkers and therapeutic targets to improve treatment options for patients with cancer (ii) elucidating mechanisms of resistance to targeted therapies, in particular PI3K and EGFR inhibitors (iii) the role of the liquid biopsy in cancer diagnosis and treatment. Dr. Gately delivers lectures to undergraduate students in Molecular Medicine as well as the MSc in Molecular Medicine and Translational Oncology. She is editor of a recent book entitled: "Lung Cancer: A Comprehensive Review" Nova Publishers 2013. Dr. Gately is currently leading a research collaboration with Inflection Biosciences Ltd, an Irish company developing targeted small molecule treatments for cancer. The research examines the effectiveness of a panel of the company's targeted PIM kinase inhibitors in the treatment of thoracic malignancy. In particular, solid tumours that have become resistant to other forms of treatment. This research is supported in part by an Innovation Partnership Program award from Enterprise Ireland (EI).
  Bioinformatics   Biological Sciences   Biology   Biomedical sciences   Biostatistical methods   Breast cancer   Cancer genetics and cell biology including metastasis   Cardiothoracic surgery   Cell Death   Cellular Biology   Clinical genetics   Clinical research, trials   Cytogenetics   Diagnostic bioimaging   Gene targeting in breast cancer   Gene therapy   Gene transcription in human cancer   Genetic/Molecular epidemiology   Genetics   Haemotology   Human genetics   Imaging Techniques   Immunoassays   Instrumentation development   Medical technology   Medicine   Molecular Biology   Molecular Genetics   Monoclonal antibodies   Natural Sciences   Quantitative and molecular genetics   Regulatory methods of gene expression   RNA processing, stability and degradation   Stem Cell Biology   Stem Cell biology and hematopoiesis   Systematic Biology   Therapeutic and Clinical oncology   Tumour immunology and immunotherapy
Language Skill Reading Skill Writing Skill Speaking
English Fluent Fluent Fluent
French Basic Basic Basic
German Basic Basic Basic
Irish Medium Medium Medium
Details Date From Date To
AACR
ETOP
BTOG
ESBB
IASLC
ESMO
Irish Thoracic Society (ITS)
ERS
Bracken-Clarke D, Kapoor D, Baird AM, Buchanan PJ, Gately K, Cuffe S, Finn SP., Vaping and lung cancer - A review of current data and recommendations., Lung cancer (Amsterdam, Netherlands), 153, 2021, p11-20 , Journal Article, PUBLISHED  DOI
Moore, G.; Lightner, C.; Elbai, S.; Brady, L.; Nicholson, S.; Ryan, R.; O'Sullivan, K.E.; O'Byrne, K.J.; Blanco-Aparicio, C.; Cuffe, S.; O'Neill, M.; Heavey, S.; Finn, S.P.; Gately, K. , Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC, Cancers, 13, (9), 2021, p2139-, Journal Article, PUBLISHED  URL
Toomey S, Carr A, Mezynski MJ, Elamin Y, Rafee S, Cremona M, Morgan C, Madden S, Abdul-Jalil KI, Gately K, Farrelly A, Kay EW, Kennedy S, O'Byrne K, Grogan L, Breathnach O, Morris PG, Eustace AJ, Fay J, Cummins R, O'Grady A, Kalachand R, O'Donovan N, Kelleher F, O'Reilly A, Doherty M, Crown J, Hennessy BT, Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples., Journal of Translational Medicine, 18, (1), 2020, p[1-99] , Journal Article, PUBLISHED  TARA - Full Text  DOI
Luszczak S, Kumar C, Sathyadevan VK, Simpson BS, Gately KA, Whitaker HC, Heavey S., PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer., Signal Transduct Target Ther., 5, (7), 2020, Journal Article, PUBLISHED  DOI
Malone T, Schäfer L, Simon N, Heavey S, Cuffe S, Finn S, Moore G, Gately K., Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer., Pharmacology and Therapeutics, 207, 2020, Journal Article, PUBLISHED  DOI
Thunnissen E, Kerr KM, Dafni U, Bubendorf L, Finn SP, Soltermann A, Biernat W, Cheney R, Verbeken E, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Tsourti Z, Geiger T, Kammler R, Peters S, Stahel RA; European Thoracic Oncology Platform Lungscape Consortium., Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort., Modern Pathology, 33, (5), 2020, p792 - 801, Journal Article, PUBLISHED
Gaule P, Mukherjee N, Corkery B, Eustace AJ, Gately K, Roche S, O'Connor R, O'Byrne KJ, Walsh N, Duffy MJ, Crown J, O'Donovan N., Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells., Cancers, 11, (4), 2019, Journal Article, PUBLISHED  DOI
Heavey S, Dowling P, Moore G, Barr MP, Kelly N, Maher SG, Cuffe S, Finn SP, O'Byrne KJ, Gately K., Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines., Scientific Reports, 8, (1), 2018, p1652-, Journal Article, PUBLISHED  TARA - Full Text  DOI
Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Losa JH, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Clark C, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Felip E, De Luca G, Savic S, Muley T, Smit EF, Dingemans AC, Priest L, Baas P, Camps C, Weder W, Polydoropoulou V, Geiger TR, Kammler R, Sumiyoshi T, Molina MA, Shames DS, Stahel RA, Peters S, ETOP Lungscape Consortium., Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project., Annals of oncology : official journal of the European Society for Medical Oncology, 29, (1), 2018, p200-208 , Journal Article, PUBLISHED  DOI
Hutchinson RA, Coleman HG, Gately K, Young V, Nicholson S, Cummins R, Kay E, Hynes SO, Dunne PD, Senevirathne S, Hamilton PW, McArt DG, Longley DB, IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer, Cell Death Discovery, 14, (3), 2017, p17050-, Journal Article, PUBLISHED
  

Page 1 of 6
kathy gately, Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer, Scientific Reports, 2020, Journal Article, PUBLISHED
Kathy Gately, Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer, Scientific Reports, 2020, Journal Article, PUBLISHED
Kathy Gately, Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer, Scientific Reports, 2020, Journal Article, PUBLISHED
Gaule P, Dasatinib, Cancers, 2019, Journal Article, PUBLISHED
Gately K, Advancing the treatment of non-small cell lung cancer - a combination approach, Cancer Professional, 2018, Journal Article, PUBLISHED
Kathy Gately, Lung Cancer : A Comprehensive Overview, First, New York U.S., Nova Science Publishers Inc, 2013, Book, PUBLISHED